CTLA4 and neoplasm: The checkpoint blockade by anti-CTLA4 antibody [157] or anti-PD1 antibody [159] showed limited clinical efficacy and it is already known that the over-expression of PD-L1 in MA tumor cells is associated with CD8+ T cells malfunction and reduction in the anti-tumoral response [163].